698 reports of this reaction
2.0% of all DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE reports
#11 most reported adverse reaction
ASTHENIA is the #11 most commonly reported adverse reaction for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 698 FDA adverse event reports linking DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE to ASTHENIA. This represents approximately 2.0% of all 35,651 adverse event reports for this drug.
Patients taking DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 698 FDA reports for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 2.0% of all adverse event reports for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, making it a notable side effect.
If you experience asthenia while taking DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.